1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

BioMarin's Cerliponase Alfa Data Support Mid-Year Submissions

 
• By Mandy Jackson

BioMarin Pharmaceutical Inc.'s cerliponase alfa (BMN 190) significantly slowed the rate of neurodegenerative decline for young patients with CLN2, a form of Batten disease, compared with historical controls in a Phase I/II clinical trial, supporting plans to seek US and EU regulatory approvals within the next few months.

BioMarin Pharmaceutical Inc.'s cerliponase alfa (BMN 190) significantly slowed the rate of neurodegenerative decline for young patients with CLN2, a form of Batten disease, compared with historical controls in a Phase I/II clinical trial, supporting plans to seek US and EU regulatory approvals within the next few months.

San Rafael, California-based BioMarin said a week ago when it reported 2015 earnings that the company expected to submit applications for cerliponase alfa to the US FDA and European Medicines...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By Joseph Haas

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

 
• By Andrew McConaghie

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

Sarepta Shares Plummet On News Of Elevidys Patient Death

 
• By Joseph Haas

The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 
• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

More from Therapy Areas

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.